Evidence map›Paper›PMID 42179445›Full record

ReviewInternational journal of cardiology. Heart & vasculature2026

Temporal therapeutic mismatch in frail older adults with heart Failure: A framework for Frailty-Informed prescribing.

Rémi Esser, Marc Harboun, Wafa Ben Ghezala, Alejandro Mondragon, Marine Larbaneix, Christine Farges, Marlène Esteban, Sophie Nisse-Durgeat, Vincenzo Palermo, Olivier Maurou

Abstract readReview
In one paragraph

Review in International journal of cardiology. Heart & vasculature, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Rémi EsserDepartment of Cardiogeriatrics, La Porte Verte Hospital, Versailles, France.
Marc HarbounDepartment of Cardiogeriatrics, La Porte Verte Hospital, Versailles, France.
Wafa Ben GhezalaDepartment of Cardiogeriatrics, Les Magnolias Hospital, Ballainvilliers, France.
Alejandro MondragonDepartment of Cardiogeriatrics, La Porte Verte Hospital, Versailles, France.
Marine LarbaneixDepartment of Cardiogeriatrics, La Porte Verte Hospital, Versailles, France.
Christine FargesDepartment of Cardiogeriatrics, La Porte Verte Hospital, Versailles, France.
Marlène EstebanDepartment of Cardiogeriatrics, La Porte Verte Hospital, Versailles, France.
Sophie Nisse-DurgeatNP MEDICAL, Medical Affairs, Bordeaux, France.
Vincenzo PalermoCardiology Department, Centre Cardiologique Marie Lannelongue, Le Plessis Robinson, France.
Olivier MaurouDepartment of Cardiogeriatrics, La Porte Verte Hospital, Versailles, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Heart failure in older adults increasingly occurs in the context of frailty, multimorbidity, and declining physiological reserve. In this population, therapeutic efficacy demonstrated in selected clinical trial populations does not automatically translate into meaningful clinical benefit. This discrepancy may create tension between guideline-driven care and goal-concordant prescribing. This narrative review proposes a conceptual framework to distinguish therapeutic efficacy from clinical relevance in ageing heart failure populations. Using tafamidis for transthyretin cardiac amyloidosis and apixaban for atrial fibrillation as illustrative paradigms, we examine how frailty severity, competing risks, life expectancy, and therapy-specific time-to-benefit influence the likelihood that a treatment will provide meaningful benefit for an individual patient. Disease-modifying therapies with delayed benefit may lose proportionality when lag-time-to-benefit exceeds the patient's anticipated window of preserved survival or functional autonomy. In contrast, preventive strategies that rapidly reduce autonomy-threatening events may retain broader clinical relevance across vulnerability strata, although individualized reassessment remains essential. We introduce the concept of temporal therapeutic mismatch, defined as a situation in which expected therapeutic benefit occurs beyond the patient's remaining functional trajectory or life expectancy. A pragmatic framework integrating frailty severity, estimated life expectancy, competing risks, therapy-specific time-to-benefit, and patient-defined goals is proposed to support proportional prescribing. In ageing cardiovascular populations, high-quality care requires moving beyond efficacy alone toward frailty-informed clinical relevance. Structured reassessment-including consideration of non-initiation or deprescribing when appropriate-represents a key component of patient-centered cardiovascular care.

Indexed as

AgedFrailtyHeart FailurePatient-Centered CareTime-to-Benefit

Identifiers

PMID42179445
PMCPMC13191248

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.